Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Coeptis Therapeutics Holdings, Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
COEP
Nasdaq
2830
coeptistx.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Coeptis Therapeutics Holdings, Inc.
COEPTIS Completes $10 Million Series A Preferred Financing Round, Reinforcing Commitment to Technological Innovation and AI Integration
- Feb 6th, 2025 1:08 pm
Coeptis Therapeutics Holdings, Inc. (COEP): Pioneering AI-Powered Marketing for Healthcare Innovation
- Jan 31st, 2025 3:12 pm
Coeptis Therapeutics Holdings Becomes COEPTIS: Embracing a Future of Technology and Innovation
- Jan 30th, 2025 1:27 pm
Coeptis Therapeutics Leverages Artificial Intelligence and Blockchain for Next-Generation Innovation
- Jan 23rd, 2025 1:09 pm
Coeptis Therapeutics Regains Compliance with Nasdaq Listing Rule 5550(a)(2)
- Jan 22nd, 2025 1:00 pm
Coeptis Therapeutics Announces First Customer Adoptions of its NexGenAI Marketing Platform
- Jan 7th, 2025 1:00 pm
Why Is Coeptis Therapeutics Stock Falling On Friday?
- Dec 27th, 2024 5:09 pm
Coeptis Therapeutics Announces Reverse Stock Split
- Dec 27th, 2024 1:15 pm
Coeptis Therapeutics Makes Bold Strides in Innovation with the Acquisition of NexGenAI Affiliates Network Platform and Launch of Coeptis Technologies
- Dec 26th, 2024 1:15 pm
Coeptis Therapeutics Unveils New Technology Division: Coeptis Technologies
- Dec 12th, 2024 1:00 pm
Coeptis Therapeutics Executes Binding Letter of Intent to Acquire Ai-powered Marketing Solutions for Biotech, Pharmaceutical and Other Industries
- Dec 3rd, 2024 1:15 pm
Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development
- Nov 7th, 2024 1:07 pm
Coeptis Therapeutics Expands License Agreement with Deverra to Include Pandemic Preparedness, and Emergency Use
- Oct 24th, 2024 12:07 pm
Coeptis Therapeutics' Chief Scientific and Medical Officer to Present at Upcoming Fall Conferences, Highlighting Progress in Universal Cell Therapy
- Oct 15th, 2024 12:07 pm
Coeptis Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing
- Sep 19th, 2024 11:07 am
Coeptis Therapeutics Chief Executive Officer, Dave Mehalick, Updates and Outlines Strategic Vision in Letter to Shareholders
- Sep 5th, 2024 12:07 pm
Coeptis Therapeutics Closes on $4.3 Million of Series A Preferred Offering
- Jun 20th, 2024 12:47 pm
Coeptis Therapeutics' Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual Meeting
- May 30th, 2024 12:47 pm
Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024
- May 8th, 2024 12:47 pm
Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting
- May 2nd, 2024 12:47 pm
Scroll